Last reviewed · How we verify
DA-9501
DA-9501 is a standardized herbal extract that modulates inflammatory and immune pathways to improve hepatic function and reduce liver injury.
DA-9501 is a standardized herbal extract that modulates inflammatory and immune pathways to improve hepatic function and reduce liver injury. Used for Chronic liver disease / Hepatic fibrosis, Drug-induced liver injury.
At a glance
| Generic name | DA-9501 |
|---|---|
| Sponsor | Hospira, now a wholly owned subsidiary of Pfizer |
| Drug class | Herbal extract / Hepatoprotective agent |
| Modality | Small molecule |
| Therapeutic area | Hepatology / Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
DA-9501 is derived from traditional herbal medicine and contains multiple bioactive compounds that work synergistically to enhance hepatocyte protection, reduce oxidative stress, and modulate inflammatory cytokine production. The extract has demonstrated hepatoprotective effects through antioxidant mechanisms and immunomodulation, supporting liver regeneration and reducing fibrosis progression in preclinical and early clinical studies.
Approved indications
- Chronic liver disease / Hepatic fibrosis
- Drug-induced liver injury
Common side effects
- Gastrointestinal disturbance
- Mild transaminase elevation
Key clinical trials
- Clinical Study to Investigate the Efficacy and the Safety of DA-9501 in Sedation During the Surgery With Epidural Anesthesia or Spinal Anesthesia Without Intubation (PHASE3)
- Study of DA-9501 In Pediatric Subjects In The Intensive Care Unit (PHASE3)
- Clinical Study to Investigate the Efficacy and the Safety of DA-9501 in Sedation During the Surgery or Medical Procedure Without Intubation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DA-9501 CI brief — competitive landscape report
- DA-9501 updates RSS · CI watch RSS
- Hospira, now a wholly owned subsidiary of Pfizer portfolio CI